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ABSTRACT
INTRODUCTION Escalated BEACOPP (escBEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, 
vincristine, procarbazine, prednisone) significantly improves overall response rates (ORRs) and prolongs 
progression ‑free survival (PFS) in patients with advanced ‑stage Hodgkin lymphoma (HL). However, 6 to 
8 cycles of escBEACOPP are associated with increased acute toxicity and late complications.
OBJECTIVES We aimed to determine the role of early positron emission tomography–computed tomog‑
raphy (PET ‑CT) response assessment in a de ‑escalation strategy.
PATIENTS AND METHODS We retrospectively analyzed 188 consecutive patients with advanced ‑stage HL 
treated at diagnosis. Patients received 2 cycles of escBEACOPP followed by an early PET ‑CT response 
assessment performed after 2 cycles of chemotherapy (PET2). Patients with an active disease continued 
therapy with escBEACOPP, while those with negative PET2 were de ‑escalated to ABVD (doxorubicin, 
bleomycin, vinblastine, dacarbazine). Radiotherapy was allowed in patients with stage IIBX.
RESULTS PET2 allowed for de ‑escalation of therapy in 141 patients (75%). Their ORR was 92.2%, with 
a complete remission (CR) rate of 91.5%; 10 ‑year PFS and overall survival (OS) were 87.2% and 95%, 
respectively. In the whole cohort, ORR was 87.8% (CR, 85.6%), while the 10 ‑year PFS and OS were 
79.3% and 89.4%, respectively. Hematological and thromboembolic complications were significantly 
more frequent in patients treated with 6 escBEACOPP cycles, including febrile neutropenia (25 patients, 
[53.2%] vs 7 [5%]), serious anemia (35 [74.5%] vs 11 [7.8%]), or thrombocytopenia (16 [34%] vs 7 [5%]) 
(P <0.001 for all comparisons with de ‑escalation strategy) as well as pulmonary embolism (3 [6.4%] 
vs 0) (P = 0.02).
CONCLUSIONS The early de ‑escalation strategy allows for effective treatment of advanced HL, with 
a comparable efficacy to that of 6 to 8 cycles of escBEACOPP, but with significantly reduced toxicity.
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and their informed choice. The regimen was of‑
fered to all patients with stages IIBX to IV, good 
performance status (0–2) according to the East‑
ern Cooperative Oncology Group, and no dis‑
abling comorbidities. Patients over 60 years old 
were excluded, and only 16 patients (8.51%) were 
over 45 years old. All patients underwent a phys‑
ical examination, full blood cell count, measure‑
ment of urea and electrolyte levels, liver function 
tests, and PET ‑CT at diagnosis. The first 2 cycles 
of escBEACOPP were followed by an early PET‑
‑CT response assessment (PET2). A complete re‑
sponse (CR) was initially defined as an inferior ac‑
tivity of involved tissues compared with mediasti‑
nal blood pool structures. In 2010, we switched to 
Deauville criteria which define CR as a PET score 
of 1 to 3.18 In responding patients, the intensity 
of the therapy was decreased, and they were as‑
signed to 4 cycles of ABVD regimen, while those 
with an active disease continued treatment with 
escBEACOPP for a total of 6 cycles. Chemother‑
apy regimens were administered in accordance 
with their original description.19,20 The average 
relative dose intensity, calculated for all cycles of 
escBEACOPP and ABVD chemotherapy, was based 
on the patient’s body surface area, planned and 
actually administered doses of drugs, and planned 
and actual dates of chemotherapy cycles. Consoli‑
dation IFRT with a total of 36 Gy was allowed for 
patients with stage IIBX.
The final response to first ‑line therapy was as‑
sessed in accordance with the original Cheson cri‑
teria21,22 and the results of PET ‑CT performed 
within a month of chemotherapy completion or 
3 months after consolidation IFRT.18 Patients 
with partial remission (PR), stable disease, or pro‑
gressive disease were regarded as treatment fail‑
ure and, wherever possible, subjected to further 
salvage therapy and autologous stem cell trans‑
plantation (ASCT).
All patients received supportive treatment per 
local standard, including prevention of tumor 
lysis syndrome; antibacterial, antiviral, or an‑
tifungal therapy, and transfusions of red blood 
cells or platelets as required. Granulocyte colony‑
‑stimulating factor was regarded mandatory dur‑
ing escBEACOPP cycles as prophylaxis of neutro‑
penic fever.
Follow ‑up visits were performed at 3 ‑month 
intervals within the first year, every 6 months 
in the second year, and every 12 months until 
the end of the fifth year. After that time, patients 
were consulted whenever new signs or symptoms 
occurred. Computed tomography scans after ther‑
apy were performed at 6, 12, and 24 months; lat‑
er, imaging studies were performed on individual 
basis, when appropriate. The survival data were 
updated in 2019, before drafting the manuscript, 
in additional visits or phone conversations.
Progression ‑free survival was defined as 
the time from onset of escBEACOPP chemother‑
apy to lymphoma progression or death. Overall 
survival was calculated as the time from the be‑
ginning of treatment to death, regardless of 
INTRODUCTION The introduction of polychemo‑
therapy regimens, consolidated when required 
with involved ‑field radiotherapy (IFRT), ren‑
dered Hodgkin lymphoma (HL) a highly curable 
disease. The most popular regimen used in HL 
is still ABVD (doxorubicin, bleomycin, vinblas‑
tine, dacarbazine), with a 5 ‑year progression‑
‑free survival (PFS) of 61% to 76% in patients 
with advanced stage of the disease.1-5 The more 
intensive regimens, such as escalated BEACOPP 
(escBEACOPP: bleomycin, etoposide, doxorubi‑
cin, cyclophosphamide, vincristine, procarba‑
zine, and prednisone), developed by the Ger‑
man Hodgkin Study Group (GHSG), improves 
the outcome of younger patients with advanced 
stages, allowing for a 5 ‑year PFS of 90%.6,7 How‑
ever, 6 to 8 cycles of escBEACOPP result in sig‑
nificant hematological toxicity and late compli‑
cations, such as secondary acute myeloid leuke‑
mia (AML), myelodysplastic syndrome (MDS), 
and infertility.8-10
The choice of the first ‑line chemotherapy regi‑
men in HL is still a matter of controversy. It is cru‑
cial to maintain the balance between disease con‑
trol and treatment ‑related adverse events (AEs). 
To avoid excess toxicity, risk ‑adapted strategies 
have been implemented. An early response assess‑
ment by 18F ‑fluorodeoxyglucose positron emis‑
sion tomography–computed tomography (PET‑
‑CT) performed after 2 cycles of chemotherapy 
(PET2) has become an accepted prognostic tool 
in classic HL. We postulated that early respond‑
ers to escBEACOPP therapy (as assessed by PET2) 
may be further efficiently treated with ABVD reg‑
imen, with a decreased number of AEs and late 
complications.11-13
PATIENTS AND METHODS Study cohort In this 
retrospective analysis, we collected data from 
188 consecutive, previously untreated patients 
with advanced HL (clinical stage III–IV or II with 
large tumor burden and concomitant general 
symptoms; IIBX–IV), who completed their en‑
tire treatment at the Department of Hematology 
at Jagiellonian University between April 2003 and 
August 2012. The diagnosis, established accord‑
ing to the 2001 or 2008 World Health Organiza‑
tion classification, was based on histopathologi‑
cal assessments of tissue samples excised before 
first ‑line therapy.14,15 The clinical stage of lympho‑
ma was assessed using the Ann Arbor classifica‑
tion with Cotswolds modification.16 The Interna‑
tional prognostic index (IPI) for HL was calculat‑
ed for all patients at diagnosis.17
The median age at baseline was 33 years (range, 
18–59 years) with a male ‑to ‑female ratio of 1.38. 
A total of 139 patients (73.9%) presented B symp‑
toms, 119 (63.3%) had stage III or IV disease, and 
69 (36.7%) had stage IIBX; 100 patients (53.2%) 
had an IPI of 3 or higher. Patient characteristics 
and demographic data are summarized in TABLE 1.
Treatment outline Patients were referred for esc‑
BEACOPP therapy based on a physician’s decision 
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Early response assessment (PET2) performed 
after the second cycle confirmed CR in 141 pa‑
tients (75%), which allowed for a decreased in‑
tensity of chemotherapy and switch from escBEA‑
COPP to ABVD regimen. Consolidation with IFRT 
was applied in 64 patients (92.8% of those with 
stage IIBX). After completion of the entire first‑
‑line therapy in the PET2 responder cohort, ORR 
was 92.2%, including 129 patients (91.5%) with 
CR and 1 patient (0.7%) with PR. Eleven patients 
(7.8%) who achieved CR on PET2 assessment 
progressed while on ABVD and continued with 
salvage high ‑dose therapy. The majority of them 
(n = 9 [81.8%]) were successfully consolidated with 
ASCT, while 2 patients (18.2%) did not respond 
to salvage therapy and died (TABLE 2). At 10 ‑year 
follow ‑up, PFS and OS in PET2 responders were 
87.2% and 95%, respectively (FIGURES 3 and 4). 
Among the 47 patients with a PET2 ‑positive scan 
who continued with 4 additional escBEACOPP 
cycles up to 6 courses, 35 (74.5%) responded to 
treatment with CR (32 patients [68.1%]) and PR 
(3 patients [6.4%]); 12 patients (25.5%) were pri‑
mary refractory and subjected to high ‑dose ther‑
apy or ASCT, with the response observed only in 
5 patients (41.7%). The inferior outcome in this 
group was confirmed by PFS and OS at 10 ‑year 
follow ‑up (55.3% and 72.3%, respectively).
According to IPI stratification, in the low ‑risk 
group (IPI, 0–2; n = 88), 96.6% of patients com‑
pleted the first ‑line treatment with CR; 1.1%, with 
PR; and 2.3% were primary refractory, with PFS 
and OS at 10 years of 93.2% and 94.3%, respec‑
tively. In the high ‑risk group (IPI, 3–7; n = 100), 
we observed CR in only 76% of patients and PR in 
3%, while 21% of patients were primary refracto‑
ry. In the high ‑risk group, PFS and OS at 10 years 
the cause. Efficacy and survival analyses were 
performed separately in low‑ and high ‑risk groups 
(with an IPI of 0–2 and 3 –7, respectively). Ad‑
verse events were assessed according to the Com‑
mon Terminology Criteria for Adverse Events 
v2.0 from April 2003 to August 2006, v3.0 from 
September 2006 to May 2009, v4.0 from June 
2009 to June 2010, and v4.03 from July 2010 to 
August 2012.23
The  study was approved by the  Bioeth‑
ics Committee of Jagiellonian University (no., 
1072.6120.59.2017). Patients provided written 
informed consent to participate in the study.
Statistical analysis Survival analysis (PFS and 
OS) was performed using Kaplan–Meier sta‑
tistics with the log ‑rank test for comparison. 
Response rates were compared by  the  Pear‑
son χ2 test. The frequency of AEs was compared 
by the χ2 test (including Yates correction). Re‑
sults were considered significant at a P value of 
less than 0.05. All statistical analyses were per‑
formed using STATISTICA software (StatSoft, 
Kraków, Poland).
RESULTS In the whole cohort (n = 188), 161 pa‑
tients achieved CR (85.6%) and 4  patients 
achieved PR (2.1%); 23 patients were regarded 
primary resistant (12.2%). At the median follow‑
‑up of 10.4 years (range, 1.3–18.4 years), the PFS 
and OS at 10 years were 79.3% and 89.4%, respec‑
tively, in the whole group (FIGURES 1 and 2, TABLE 2). 
Among all analyzed patients, 21 deaths occurred 
(16 in high ‑risk patients according to IPI, 13 high‑
‑risk cases according to PET2); 20 deaths were 
caused by HL and 1 death resulted from a traf‑
fic accident.
TABLE 1 Patient characteristics and demographic data
Age, y, median (range) 33 (18–59)
Age 18–24 years 108 (57.4)
25–44 years 64 (34)
45–59 years 16 (8.51)
Male sex 109 (58)
ECOG performance status, median (range) 1 (0–2)
Histological subtype of lymphoma Nodular sclerosis 142 (75.5)
Mixed cellularity 3 (1.6)
Lymphocyte rich 2 (1.1)
Lymphocyte depleted 2 (1.1)
Unclassified 39 (20.7)
Ann Arbor IIBX 69 (36.7)
III 45 (23.9)
IV 74 (39.4)
Bulky disease 125 (66.5)
B symptoms 139 (73.9)
International prognostic index 0–2 88 (46.8)
3–7 100 (53.2)
Data are presented as number (percentage) unless otherwise indicated.
Abbreviations: ECOG, Eastern Cooperative Oncology Group
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chemotherapy dose adjustment was necessary due 
to neutropenia. The cumulative dose of doxoru‑
bicin was 270 mg/m2 in the PET2 ‑negative arm 
and 200 mg/m2 in the PET2 ‑positive arm. There 
were no episodes of early or late cardiotoxicity or 
treatment discontinuation in this group.
Adverse events of any grade occurred in 140 pa‑
tients (74.5%). The most frequent AEs were neu‑
tropenia (grade 1–2, 56.9%; grade 3–4, 66%), ane‑
mia (grade 1–2, 83%; grade 3–4, 24.5%), thrombo‑
cytopenia (grade 1–2, 48.4%; grade 3–4, 12.2%), 
febrile neutropenia (no episodes of grade 1–2; 
grade 3–4, 17%). Serious AEs occurred in 26% of 
patients, with febrile neutropenia being the most 
were 67% and 85%, respectively. Response rates 
to treatment according to the IPI and PET2 re‑
sults are presented in TABLE 2.
The average relative dose intensity of escBEA‑
COPP and ABVD regimens was 84% and 96%, 
respectively. The average relative dose intensi‑
ty of the entire treatment was 91%, which was 
above the recently recommended 90% in lym‑
phoma therapy.24 Overall, 35  of the  188  pa‑
tients (19%) required at least one dose reduc‑
tion during treatment with escBEACOPP; in 
29 cases, bleomycin and vincristine infusion 
was omitted on the eighth day of treatment 
because of neutropenia. In ABVD regimen, no 
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FIGURE 1 Progression‑
‑free survival analysis in 
the whole cohort 
(188 patients)
FIGURE 2 Overall 
survival analysis in 
the whole cohort 
(188 patients)
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We did not formally assess fertility, but it 
should be noted that 48 pregnancies have been 
reported after completion of therapy (28 wom‑
en and the wives of 20 male patients). Assisted 
reproduction was required in 5 cases, all treated 
with 6 cycles of escBEACOPP, 2 of them with con‑
solidated IFRT, and 1 after ASCT.
DISCUSSION There are continuous efforts to de‑
velop an effective strategy with acceptable tox‑
icity for patients with advanced ‑stage HL. PET‑
‑adapted strategies provide improved control of 
the disease without an increase in toxicity. In 
frequent one. Apart from hematological toxicity, 
the most common complications of grade 3 or 
4 were thromboembolic events (exact pulmonary 
embolism) in 1.6% of patients. Hematological AEs 
and thromboembolic complications were signif‑
icantly more frequent in patients treated with 
6 escBEACOPP cycles (TABLE 3).
During the median follow ‑up of 10.4 years, we 
did not observe MDS or AML. The only secondary 
cancers reported were 4 cases of basal cell skin 
carcinoma and 2 cases of breast cancer, all in pa‑
tients treated with 6 escBEACOPP cycles. There 
were no deaths related to AEs.
TABLE 2 Comparison of outcome in relationship to baseline international prognostic index or positron emission tomography results and 
chemotherapy de ‑escalation strategy
All, 
n
CR, 
n (%)
PR, 
n (%)
SD + PD, 
n (%)
Relapse, 
n (%)
Mortality, 
n (%)
PFS at 10 years, % OS at 10 years, %
IPI for HL
Low ‑risk 0–2 88 85 (96.6) 1 (1.1) 2 (2.3) 4 (4.5) 5 (5.7) 93.2 94.3
High ‑risk ≥3 100 76 (76) 3 (3) 21 (21) 12 (12) 16 (16) 67 85
P value <0.001 0.1 0.03 <0.001 0.03
Early response assessment by PET
PET2 negative 141 129 (91.5) 1 (0.7) 11 (7.8) 7 (5) 8 (5.7) 87.2 95
PET2 positive 47 32 (68.1) 3 (6.4) 12 (25.5) 9 (19.1) 13 (27.7) 55.3 72.3
P value <0.001 0.003 <0.001 <0.001 <0.001
Complete study cohort
All patients 188 161 (85.6) 4 (2.1) 23 (12.2) 16 (8.5) 21 (11.2) 79.3 89.4
Abbreviations: CR, complete remission; IPI, International Prognostic Index; OS, overall survival; PD, progressive disease; PET2, positron emission 
tomography result after 2 cycles of chemotherapy; PFS, progression ‑free survival; PR, partial remission; SD, stable disease
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(log ‑rank test, P <0.001)
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for patients treated in the escBEACOPP arm 
according to the HD18 protocol, allowing for 
a shortened therapy in PET2 responders (4 × es‑
cBEACOPP) and adding rituximab in patients 
with an active disease on PET2 (2 × escBEACOPP 
+ 6 × R ‑BEACOPP).25 In our analysis, in the whole 
cohort, PFS and OS at 10 years were 83% and 
90%, respectively. Although the PFS at 5 years 
was lower in our study than in the GHSG stud‑
ies, a 10 ‑year follow ‑up allowed us to demon‑
strate a durable benefit of less intensive treat‑
ment, with no relapses after 6 years. Our PET2‑
‑negative patients achieved even better results 
at 10 years (PFS, 87.2%; OS, 95%), without long‑
‑lasting complications.
Patients included in the analysis were treat‑
ed before targeted therapies, such as anti‑
‑CD30 monoclonal antibodies (brentuximab ve‑
dotin [BV]), or checkpoint inhibitors were avail‑
able. Originally approved for relapsing or re‑
fractory cases, BV has been recently tested in 
the first ‑line setting. In the ECHELON ‑1 study, 
1334 treatment ‑naive patients with advanced 
HL were randomized to ABVD vs BV plus AVD 
(ABVD without bleomycin, which was substitut‑
ed by BV).26 At 2 years, modified PFS, the prima‑
ry target of the study, in the BV ‑plus ‑AVD arm 
was 82.1%.26 Adverse events were relatively fre‑
quent: 43% of the patients experienced serious 
AEs, 37% had to be hospitalized, and 67% devel‑
oped long ‑lasting peripheral neuropathy.26 Al‑
though a direct comparison with our results is 
not possible (there were more elderly patients 
patients treated with an upfront escBEACOPP 
regimen, the negative predictive value of PET2 
for PFS was 98%.11 We presented a de ‑escalation 
protocol guided by early PET ‑CT response as‑
sessment performed after the second cycle of 
escBEACOPP, which allowed a de ‑escalation to 
ABVD regimen in 75% of patients. A random‑
ized comparison (AHL2011 [PET‑adapted treat‑
ment for newly diagnosed advanced Hodgkin 
lymphoma] study) of 6 escBEACOPP cycles, re‑
garded as a standard arm, with PET ‑driven de‑
‑escalation in patients responding to the first 
2 cycles (2 × escBEACOPP followed by 4 × ABVD) 
showed equal efficacy and decreased toxicity be‑
tween approaches.13 Our protocol was identical 
to the experimental arm of the AHL2011 study; 
however, the median follow ‑up time was twice as 
long (10.4 vs 4.2 years). In the AHL2011 study, 
the projected 5 ‑year PFS in the experimental arm 
was 85.7%. An increased risk of progression or 
relapse was associated with positive results in 
PET2 (5 ‑year PFS in the PET2 ‑negative group vs 
the PET2 ‑positive group was 70.7% vs 88.9%, P 
<0.0001).13 A multivariable analysis proved that 
an early PET ‑CT assessment had a prognostic val‑
ue independent of IPI.13 In the AHL2011 study, 
the outcome of patients treated in the standard 
arm (6 cycles of escBEACOPP) was similar to that 
reported with the same regimen in the HD15 
protocol of GHSG, comparing 8 and 6 cycles of 
escBEACOPP with 8 cycles of baseline BEACOPP 
14 (PFS at 5 years was 90.3%).7,13 Progression‑
‑free survival was also similar (91.4% at 3 years) 
FIGURE 4 Overall 
survival analysis in 
relationship to positron 
emission tomography 
results and chemotherapy 
de ‑escalation strategy 
(log ‑rank test, P <0.001)
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or AML. Toxicity in PET2 ‑negative patients de‑
‑escalated to ABVD in the AHL2011 study was 
comparable to our results and lower than in pa‑
tients treated with 4 cycles of escBEACOPP in 
the HD18 study.13,25 There were fewer cases of 
anemia (grade ≥3) (24% vs 39%) and thrombocy‑
topenia (36% vs 57%), similar rates of leukopenia 
(including febrile neutropenia), and bleomycin‑
‑related pulmonary toxicity was not observed.25 
Additionally, in the GHSG HD9 study,6 after 
the median follow ‑up of 9.25 years, in the arm 
treated with 8 cycles of escBEACOPP, an increased 
incidence of secondary malignancies was report‑
ed (overall, 6%, including 3% for AML and 1.9% 
for solid tumors).6
The identified 9% rate of thromboembolic 
events prompts questions as to how the opti‑
mal primary thromboprophylaxis should be de‑
fined, especially in patients treated with escBEA‑
COPP.27 Overt cardiotoxicity was not observed in 
our study, which makes a significant difference 
in comparison with patients with non–Hodgkin 
lymphoma, who are older and more likely to have 
cardiovascular comorbidities.28
The principal aim of our study was to deter‑
mine in a real ‑life setting whether an interim PET‑
‑CT–guided de ‑escalation strategy will maintain 
its high efficiency and reduce the number of AEs 
and late complications. The single ‑center, retro‑
spective analysis has several limitations, includ‑
ing the possibility of an involuntary patient se‑
lection and the lack of an independent PET ‑CT 
assessment. However, the long median follow‑
‑up duration, exceeding 10 years, relatively low 
in the ECHELON ‑1 study), BV in the first line is 
an alternative, not a breakthrough. Therefore, 
especially in countries with lower economic sta‑
tus, BV is unlikely to become the new standard 
of care in the first ‑line therapy.
Of note, we observed 11 patients (7.8%) with 
negative PET2 results to progress while on ABVD 
therapy (1 low ‑risk patient and 10 high ‑risk pa‑
tients according to IPI); thus, although early PET2 
assessment remains a predictor of good prog‑
nosis, it cannot serve as a surrogate of CR. We 
observed 12 primary ‑resistant cases (25.5%) in 
the PET2 ‑positive group; further intensive ther‑
apy resulted in a 10 ‑year PFS and OS of 55.3% 
and 72.3%, respectively.
In our early de ‑escalation strategy, IPI re‑
mained an important prognostic factor for both 
PFS and OS. High ‑risk patients according to IPI, 
when compared with low ‑risk patients, had a 
lower response rate (CR, 96.6% vs 76%) and 
higher relapse rate (4.5% vs 12%). Both low IPI 
and good clinical response on PET2 assessment 
allowed us to identify a favorable prognostic sub‑
group in patients with advanced HL, with an OS 
of 94% to 95% at 10 years. However, IPI for HL 
allowed us to identify only 88 cases (46%) be‑
longing to a favorable prognostic subgroup, while 
an early PET assessment doubled this number to 
141 patients (75%). Therefore, our data strong‑
ly suggest that PET2 is a better tool to identify 
low ‑risk patients.
In our analysis, we observed lower rates of AEs, 
elimination of bleomycin ‑related pulmonary tox‑
icity, as well as no secondary solid tumors, MDS, 
TABLE 3 Comparison of adverse event occurrence during chemotherapy
Adverse eventsa All patients
n = 188
Grade
1–2
P value Grade
3–4
P value
Grade 1–2, 
n (%)
Grade 3–4, 
n (%)
PET2 ‑negative 
group 
(n = 141), 
n (%)
PET2 ‑positive 
group 
(n = 47), 
n (%)
PET2‑
‑negative 
group 
(n = 141), 
n (%)
PET2 ‑positive 
group 
(n = 47), 
n (%)
Neutropenia 107 (56.9) 124 (66) 62 (44) 45 (95.7) <0.001 82 (58.2) 42 (89.4) 0.002
Febrile neutropenia 0 32 (17) 0 0 – 7 (5) 25 (53.2) <0.001
Anemia 156 (83) 46 (24.5) 124 (87.9) 32 (68.1) 0.002 11 (7.8) 35 (74.5) <0.001
Thrombocytopenia 91 (48.4) 23 (12.2) 46 (32.6) 45 (95.7) <0.001 7 (5) 16 (34) <0.001
Sepsis 0 2 (1.1) 0 0 – 0 2 (4.3) 0.1
Pneumonia 9 (4.8) 0 2 (1.4) 7 (14.9) <0.001 0 0 –
Peripheral neuropathy 38 (20.2) 0 20 (14.2) 18 (38.3) <0.001 0 0 –
AST or ALT elevation 55 (29.3) 2 (1.1) 16 (11.3) 39 (83) <0.001 1 (0.7) 1 (2.1) 1.0
Cardiotoxicity 0 0 0 0 – 0 0 –
Tumor lysis syndrome 0 0 0 0 – 0 0 –
Thromboembolic event 14 (7.4) 3 (1.6) 5 (3.5) 9 (19.1) 0.001 0 3 (6.4) 0.02
Vomiting 57 (30.3) 0 15 (10.6) 42 (89.4) <0.001 0 0 –
Diarrhea 32 (17) 0 8 (5.7) 24 (51.1) <0.001 0 0 –
Mucositis 46 (24.5) 1 (0.5) 11 (7.8) 35 (74.5) <0.001 0 1 (2.1) 0.6
a Adverse events were assessed according to Common Terminology Criteria for Adverse Events (see the PATIENTS AND METHODS section).
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase
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therapy ‑related toxicity, and the exceptionally 
good PFS and OS remain the meaningful value 
of our analysis.
In summary, the early PET ‑driven strategy al‑
lowed for de ‑escalation of upfront escBEACOPP 
regimen in 75% of patients with advanced ‑stage 
HL and improved tolerability of therapy without 
impairing its long ‑term results.
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